Arcutis Biotherapeutics Inc

자세한 내용은 Arcutis Biotherapeutics Inc 회사

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.

회사 정보

종목 코드 ARQT

회사 이름Arcutis Biotherapeutics Inc

상장일Jan 31, 2020

CEOMr. Todd Franklin Watanabe

직원 수342

유형Ordinary Share

회계 연도 종료Jan 31

주소3027 Townsgate Road

도시WESTLAKE VILLAGE

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호91361

전화18054185006

웹사이트https://arcutis.com/

종목 코드 ARQT

상장일Jan 31, 2020

CEOMr. Todd Franklin Watanabe

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Bhaskar Chaudhuri, Ph.D.

Independent Director

917.81K

+0.84%

Mr. Todd Franklin Watanabe

President, Chief Executive Officer, Director

721.32K

-0.28%

Dr. Howard G. Welgus, M.D.

Independent Director

100.21K

-8.42%

Mr. Masaru (Mas) Matsuda, Esq., J.D.

Senior Vice President, General Counsel

78.26K

-8.03%

Ms. Latha Vairavan

Chief Financial Officer, Senior Vice President

65.10K

--

Ms. Sue-Jean Lin

Independent Director

26.73K

+39.78%

Mr. Patrick J. Heron

Independent Chairman of the Board

26.43K

+40.42%

Ms. Neha Krishnamohan

Independent Director

23.36K

+48.32%

Ms. Terrie J. Curran

Independent Director

--

Ms. Halley E. Gilbert, J.D.

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Dr. Bhaskar Chaudhuri, Ph.D.

Independent Director

917.81K

+0.84%

Mr. Todd Franklin Watanabe

President, Chief Executive Officer, Director

721.32K

-0.28%

Dr. Howard G. Welgus, M.D.

Independent Director

100.21K

-8.42%

Mr. Masaru (Mas) Matsuda, Esq., J.D.

Senior Vice President, General Counsel

78.26K

-8.03%

Ms. Latha Vairavan

Chief Financial Officer, Senior Vice President

65.10K

--

Ms. Sue-Jean Lin

Independent Director

26.73K

+39.78%

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sat, May 17

주주

주주 유형

주주

비율

Suvretta Capital Management, LLC

9.58%

Jennison Associates LLC

9.32%

Rubric Capital Management LP

9.20%

Frazier Life Sciences Management, L.P.

7.37%

BlackRock Institutional Trust Company, N.A.

6.63%

Other

57.89%

주주

비율

Suvretta Capital Management, LLC

9.58%

Jennison Associates LLC

9.32%

Rubric Capital Management LP

9.20%

Frazier Life Sciences Management, L.P.

7.37%

BlackRock Institutional Trust Company, N.A.

6.63%

Other

57.89%

주주 유형

주주

비율

Investment Advisor

32.24%

Investment Advisor/Hedge Fund

31.96%

Hedge Fund

29.96%

Private Equity

7.39%

Research Firm

4.30%

Individual Investor

2.19%

Venture Capital

1.84%

Sovereign Wealth Fund

0.45%

Bank and Trust

0.42%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

477

132.39M

111.07%

-21.95M

2025Q1

487

132.87M

111.51%

-24.00M

2024Q4

453

136.04M

114.96%

-23.73M

2024Q3

433

136.12M

116.66%

-19.10M

2024Q2

416

134.94M

116.78%

-20.37M

2024Q1

392

131.83M

115.81%

+2.26M

2023Q4

366

104.30M

108.66%

+5.22M

2023Q3

364

79.57M

131.78%

-15.32M

2023Q2

359

84.02M

139.44%

-6.66M

2023Q1

352

83.59M

140.11%

+3.40M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Suvretta Capital Management, LLC

11.42M

9.58%

+23.84K

+0.21%

Mar 31, 2025

Jennison Associates LLC

11.36M

9.53%

-978.92K

-7.93%

Mar 31, 2025

Rubric Capital Management LP

10.97M

9.2%

--

Mar 31, 2025

Frazier Life Sciences Management, L.P.

8.79M

7.37%

--

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

7.91M

6.63%

-197.41K

-2.44%

Mar 31, 2025

The Vanguard Group, Inc.

6.79M

5.7%

+373.66K

+5.82%

Mar 31, 2025

Polar Capital LLP

6.71M

5.63%

-670.91K

-9.09%

Mar 31, 2025

State Street Global Advisors (US)

4.47M

3.75%

-476.52K

-9.63%

Mar 31, 2025

Gilder Gagnon Howe & Co. LLC

4.10M

3.44%

+193.06K

+4.95%

Mar 31, 2025

Morgan Stanley & Co. LLC

3.08M

2.58%

-403.45K

-11.59%

Mar 31, 2025

14.325USD

Arcutis Biotherapeutics Inc

14.325

개요

회사

금융